Literature DB >> 7542498

Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages.

J B Weinberg1, M A Misukonis, P J Shami, S N Mason, D L Sauls, W A Dittman, E R Wood, G K Smith, B McDonald, K E Bachus.   

Abstract

Nitric oxide (NO) is produced by numerous different cell types, and it is an important regulator and mediator of many processes including smooth muscle relaxation, neurotransmission, and murine macrophage-mediated cytotoxicity for microbes and tumor cells. Although murine macrophages produce NO readily after activation, human monocytes and tissue macrophages have been reported to produce only low levels of NO in vitro. The purpose of this study was to determine if stimulated human mononuclear phagocytes produce inducible nitric oxide synthase (iNOS) mRNA, protein, and enzymatic activity. By reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, we show that human monocytes can be induced to express iNOS mRNA after treatment with lipopolysaccharide (LPS) and/or interferon-gamma (IFN-gamma). By immunofluorescence and immunoblot analyses, we show monocytes and peritoneal macrophages contain detectable levels of iNOS antigen after stimulations with cytokines in vitro. Control monocytes or those cultured with LPS and/or various cytokines have low levels of NOS functional activity as measured by the ability of cell extracts to convert L-arginine to L-citrulline, and they produce low levels of the NO catabolites nitrite and nitrate. Peritoneal macrophages have significantly enhanced nitrite/nitrate production and NOS activity after treatment with LPS and/or IFN-gamma, whereas monocyte nitrite/nitrate production and NOS activity are not altered by the treatments. Monocytes cultured with various live or heat-killed bacteria, fungi, or human immunodeficiency virus (HIV)-1 do not produce high levels of nitrite/nitrate. Antibodies against transforming growth factor-beta (TGF-beta), a factor known to inhibit iNOS expression and NO production in mouse macrophages, do not enhance NO production in human monocytes or macrophages. Biopterin, an obligate cofactor of iNOS enzymatic activity, is undetectable in freshly isolated or cultured human monocytes and peritoneal macrophages. However, replenishment of intracellular levels of tetrahydrobiopterin by culture with the cell-permeable, nontoxic precursor sepiapterin does not enhance the abilities of the human mononuclear phagocytes to produce NO in vitro. Mixing experiments show no evidence of a functional NOS inhibitor in human mononuclear phagocytes. Thus, we demonstrate that human mononuclear phagocytes can produce iNOS mRNA and protein, and (despite this) their abilities to generate NO are very low.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542498

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  116 in total

1.  Dimerization of major histocompatibility complex class I on the surface of THP-1 cells stimulates the expression of inducible nitric oxide synthase and subsequent nitric oxide release.

Authors:  G Bottley; N Fernández
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

2.  C/EBPβ regulates the M2 transcriptome in β-adrenergic-stimulated macrophages.

Authors:  Donald M Lamkin; Shreyesi Srivastava; Karen P Bradshaw; Jenna E Betz; Kevin B Muy; Anna M Wiese; Shelby K Yee; Rebecca M Waggoner; Jesusa M G Arevalo; Alexander J Yoon; Kym F Faull; Erica K Sloan; Steve W Cole
Journal:  Brain Behav Immun       Date:  2019-05-24       Impact factor: 7.217

3.  Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.

Authors:  Matthew J Kan; Jennifer E Lee; Joan G Wilson; Angela L Everhart; Candice M Brown; Andrew N Hoofnagle; Marilyn Jansen; Michael P Vitek; Michael D Gunn; Carol A Colton
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

4.  p47 GTPases regulate Toxoplasma gondii survival in activated macrophages.

Authors:  Barbara A Butcher; Robert I Greene; Stanley C Henry; Kimberly L Annecharico; J Brice Weinberg; Eric Y Denkers; Alan Sher; Gregory A Taylor
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

5.  Inhibition of nitric oxide synthase by cobalamins and cobinamides.

Authors:  J Brice Weinberg; Youwei Chen; Ning Jiang; Bethany E Beasley; John C Salerno; Dipak K Ghosh
Journal:  Free Radic Biol Med       Date:  2009-03-27       Impact factor: 7.376

6.  Anticancer and immunostimulatory role of encapsulated tumor antigen containing cobalt oxide nanoparticles.

Authors:  Sourav Chattopadhyay; Sandeep Kumar Dash; Totan Ghosh; Sabyasachi Das; Satyajit Tripathy; Debasis Mandal; Debasis Das; Panchanan Pramanik; Somenath Roy
Journal:  J Biol Inorg Chem       Date:  2013-09-17       Impact factor: 3.358

Review 7.  Malarial hemozoin: from target to tool.

Authors:  Lorena M Coronado; Christopher T Nadovich; Carmenza Spadafora
Journal:  Biochim Biophys Acta       Date:  2014-02-17

8.  The fornix provides multiple biomarkers to characterize circuit disruption in a mouse model of Alzheimer's disease.

Authors:  Alexandra Badea; Lauren Kane; Robert J Anderson; Yi Qi; Mark Foster; Gary P Cofer; Neil Medvitz; Anne F Buckley; Andreas K Badea; William C Wetsel; Carol A Colton
Journal:  Neuroimage       Date:  2016-08-10       Impact factor: 6.556

9.  Cell-based assays that predict in vivo neurotoxicity of urban ambient nano-sized particulate matter.

Authors:  Hongqiao Zhang; Amin Haghani; Amirhosein H Mousavi; Mafalda Cacciottolo; Carla D'Agostino; Nikoo Safi; Mohammad H Sowlat; Constantinos Sioutas; Todd E Morgan; Caleb E Finch; Henry Jay Forman
Journal:  Free Radic Biol Med       Date:  2019-09-19       Impact factor: 7.376

10.  CCTTT-repeat polymorphism of the inducible nitric oxide synthase is not associated with HIV pathogenesis.

Authors:  M Hersberger; S Bonhoeffer; S K Rampini; M Opravil; J Marti-Jaun; A Telenti; E Hänseler; B Ledergerber; R F Speck
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.